ACBNasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends March 31

AURORA CANNABIS INC

Financials through Q4 FY2025, quarter ended Mar 31, 2025Last filing: 40-F on Jun 11, 2026

$3.96−0.03 (-0.75%)

Close on Oct 19, 2026

Debt

Borrowings on the balance sheet, Mar 31, 2025

Total debt

C$42.49M

C$2.30M due within a year

Net debt

-C$95.43M

After C$137.92M of cash

Implied interest rate

39.63%

FY2025 interest ÷ average debt

Interest coverage

0.6×

FY2025 operating income ÷ interest

Total debt by fiscal year

Long-term plus current debt, CAD

Bond issues

Individual notes and bonds outstanding

Bond-level data is not connected yet

Coupon, maturity and amount of each note will come from the debt footnote in Aurora Cannabis's annual report. Trading prices and yields need FINRA TRACE data.

Where these numbers come from

Parsed from the XBRL in Aurora Cannabis's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-10 reverse split on Feb 20, 2024
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ACB.

Revenue growth55.1% · median 22.1%

Gross margin54.6% · median 35.5%

Operating margin1.4% · median -28.1%

Company	Revenue	Growth
ACB	C$343.29M	+55.1%
CGC	C$293.63M	+6.8%
CRON	$179.09M	+37.5%
CRLBF	–	–
IMCC	–	–
CURLF	–	–

Company

Exchange: Nasdaq
Industry: Medicinal Chemicals & Botanical Products
Fiscal year ends: March 31
Held by institutions: 8.9%
Auditor: Ernst & Young LLP
SEC CIK: 1683541

Advertisement
300 × 250